Leveragen Forms Collaboration with Moderna to Enhance Therapeutics Using Unique Fully Human Single Domain Antibody Technology
Wednesday, July 31, 2024
Leveragen, Inc., a Boston-based biotech startup, has announced a new multi-target research, option, and license agreement with Moderna, Inc. Leveragen will use its proprietary single domain antibody discovery platform to create optimized binding modules for therapeutic targets chosen by Moderna. Moderna will have the option to obtain exclusive rights for the development and commercialization of these therapeutic products.
Leveragen, explained, “Conventional models for single domain antibody discovery often face challenges such as limited antibody diversity and inadequate immune responses due to the limitations of traditional transgenic technologies. Our innovative Singularity Sapiens Mouse model addresses these issues by providing a complete human VH repertoire and strong immune responses. This partnership with Moderna aims to advance the use of single domain antibodies in mRNA therapeutics and explore new opportunities to meet unmet medical needs.”
As part of the agreement, Leveragen will drive the discovery of single domain antibody sequences for various targets. If Moderna opts to move forward, it will manage further development and commercialization. Leveragen will receive an undisclosed upfront payment, research funding, and potential milestones for development, regulatory approval, and commercialization, in addition to tiered royalties based on global sales.
Source: leveragen.com
